Loading stock…

Globus Medical, Inc. (GMED) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Globus Medical, Inc.

GMEDMarket cap $10BPrice $76.4

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Designs and manufactures spine, orthopedic, and robotic surgery devices used by surgeons worldwide. Its robotic-assisted platforms are reshaping spine surgery, and after merging with NuVasive, it's now one of the largest musculoskeletal device makers on the planet.

In Bastion Portfolios?

52W Return+28%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+42%10

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+7%5

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+29%8

EPS Growth Y+2+8%6

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin23%8

Net Income Margin17%7

Free Cash Flow Margin24%9

Debt

Net Debt/EBITDA-0.710

Efficiency

ROE12%5

ROA10%9

Earnings Stability77

GEAR+VERY STRONG92

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)136

P/BV2.26

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd118

Yield

Free Cash Flow Yield7.4%8

Dividend Yieldna–

Momentum

Short term

1 month return-2%6

3 month return-3%5

YTD return-12%3

Mid term

Price vs 52wHigh75%4

1 year return+29%8

Long term

3 year return+45%5

5 year return-2%3

Risk Shield

Price Risk

Beta0.76

Volatility45%4

Free Cash Flow

Free Cash Flow Margin24%9

Free Cash Flow Yield7.4%8

Quality

ROCE15%8

Earnings Stability77

Net Debt/EBITDA-0.710

02Growth

Is it actually growing, and how fast?

GMEDGlobus Medical

Revenue FY25$2.9B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+42%10

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+29%8

EPS growth, FY27E+8%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 42%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 42%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE41 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-3%5

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+29%8

3-year return+45%5

5-year return-2%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+45% over three years and -2.3% over five), roughly average for the market.

It's up 29% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-2%) and over three months (-3%).

WEAKNESSES

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Globus Medical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GMEDGlobus Medical

Revenue FY25$2.9B

GROWTH RATING↗

AVERAGE61 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+42%10

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+29%8

EPS growth, FY27E+8%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 42%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 61% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, a little ahead of the market.6/10

Revenue grew 42%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE41 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%6

3-month return-3%5

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high75%4

1-year return+29%8

3-year return+45%5

5-year return-2%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Average long-term results. Multi-year returns are middling (+45% over three years and -2.3% over five), roughly average for the market.

It's up 29% over the past year, but 25% below its 52-week high. That is a touch ahead of the market.

Returns sit at the market level over the past month (-2%) and over three months (-3%).

WEAKNESSES

The stock is underperforming so far this year (-12%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Globus Medical, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community